

Status Of Vitamin D, Parathyroid Hormone And Carotid Artery Intima Media Thickness And Its Correlation With Estimated Glomerular Filtration Rate In Patients With Chronic Kidney Disease

Dr. D.S.S.K. Raju^{1*}, B. Harsha Vardhan², Dr. Vinayak Ganesh Bhat³, Dr. S.J Basha⁴,

¹Assistant Professor, Department of Biochemistry, Maharajah's Institute of Medical Sciences Nellimarla, Vizianagaram, Andhra Pradesh - India - 535217.

²House surgeon, Maharajah's Institute of Medical Sciences Nellimarla, Vizianagaram Andhra Pradesh - India - 535217.

³Assistant Professor, Department of Biochemistry, Maharajah's Institute of Medical Sciences Nellimarla, Vizianagaram Andhra Pradesh - India - 535217.

⁴Professor & HOD, Department of Biochemistry, Maharajah's Institute of Medical Sciences Nellimarla, Vizianagaram Andhra Pradesh - India - 535217.

*Corresponding Author:- Dr. D.S.S.K. Raju,

Assistant Professor, Department of Biochemistry, Maharajah's Institute of Medical Sciences Nellimarla, Vizianagaram, Andhra Pradesh - India - 535217. Email id. dsskraju@gmail.com

DOI: 10.47750/pnr.2022.13.508.652

Abstract

Chronic kidney disease the most common feature is hypovitaminosis D leading to secondary hyperparathyroidism. This would have caused an increase in calcium and a decrease in phosphate levels. Arterial wall thickness can be measured by carotid intima media thickness test. Early detection of these changes may hint the need for a more aggressive approach towards heart disease and stroke. Ethical committee approval was obtained by Institutional Ethical committee. The study consists of 60 CKD patients divided into 3 groups based on eGFR and 20 normal healthy individuals, age and sex matched individuals between the age group of 30-60 years. Informed consent was taken from the patients and controls. Demographic data was collected followed by history regarding current health status, history of medication, alcoholism and Active smoking. Serum creatinine was estimated by alkaline picrate method, blood urea was estimated by Urease method, serum calcium level was estimated by OCPC method and serum phosphorous was estimated by Ammonium Molybdate method. Serum 25 OH vitamin D and serum will be analyzed by ELISA method. Serum PTH was estimated by ELISA method. Carotid artery ultrasound scans will be recorded for each participant with a 10-MHz linear-array transducer to measure intima media thickness. This study helpful to label an early alarming marker to prevent the worst progression of CKD by estimating Vitamin D, PTH and CIMT. The progression and complications of CKD, especially the cardiovascular complications can be prevented or at least postponed to some extent.

Keywords: Chronic kidney disease, Vitamin D, parathyroid hormone, carotid intima media thickness, estimated GFR

INTRODUCTION

Chronic Kidney Disease (CKD) is characterized by irreversible sclerosis and loss of nephrons. The renal mass progressively declines over a prolonged period, depending on the underlying etiology [1]. CKD patients are classified five stages based on Glomerular Filtration Rate (GFR). Diabetes and hypertension could stand as the main etiology for the increased incidence of CKD. It affects 10-16% of the adult population worldwide [2]. In India, the recent estimate is found to be 229 per million population [3]. The National Kidney Foundation (NKF) Task Force on Cardiovascular Disease in CKD demonstrated the prevalence of cardiovascular disease in CKD and associated high death rate [4].

Vitamin D is well known factor that regulates bone and mineral metabolism by promoting calcium, phosphate absorption and suppressing Parathyroid hormone (PTH) secretion [5]. It is renoprotective with suppression of the renin-angiotensin-aldosterone system, and with anti proteinuric as well as anti-inflammatory effects [6]. It has antiatherosclerotic role that includes inhibition of macrophage to foam cell formation, down regulation of vascular smooth muscle cell proliferation and migration and suppression of inflammation triggered expression of endothelial adhesion molecules. Besides, vitamin D also prevents vascular calcification by inhibition of bone morphogenetic protein-2 expression. Decreased vitamin D can cause low calcium and hyperparathyroidism. PTH normally causes absorption of calcium and excretion of phosphorous [7].

In CKD the most common feature is hypovitaminosis D leading to secondary hyperparathyroidism. This would have caused an increase in calcium and a decrease in phosphate levels. But due to the declined renal mass, this does not happened PTH secretions further stimulated [8]. These may alter the vascular smooth muscle cell proliferation and reprogram the osteoblastic changes, finally leading to increase arterial wall thickness [9]. Arterial wall thickness can be measured by carotid intima media thickness test (CIMT) and the extent of carotid

atherosclerotic vascular disease may be estimated. The test measures the thickness of the inner two layers of the carotid artery, the intima and the media. Early detection of these changes may hint the need for a more aggressive approach towards heart disease and stroke [10].

Though CKD can have a deleterious consequence of CVD and increased mortality, estimation of Vitamin D, PTH, Calcium, Phosphorous and Measuring CIMT might throw a warning sign of the future risk. Early intervention could help the CKD patients for a better life and outcome. The aim of present study is evaluate the status of Vitamin D, Parathyroid hormone and Carotid artery Intima Media Thickness and its Correlation with estimated Glomerular Filtration Rate in patients with Chronic Kidney Disease.

MATERIAL AND METHODS

Type of study

Case - Control study.

Study Population

Study population was patients and attendants who attend the Department of Nephrology.

Sample size

80 in which 20 will be normal healthy individuals and 60 will be CKD patients with stage 3 to 5.

Selection Criteria

Inclusion Criteria

The patients attending Nephrology Department diagnosed with CKD.

Exclusion Criteria

Known Subjects with history of smoking, alcoholism and medicines which influence serum calcium and vitamin D levels was excluded. Patients with any debilitating illness also excluded from the study.

Study design

Ethical committee approval was obtained by Institutional Ethical committee. The study consists of 60 CKD patients divided into 3 groups based on GFR and 20 normal healthy individuals, age and sex matched individuals between the age group of 30-60 years. Informed consent was taken from the patients and controls. Demographic data was collected followed by history regarding current health status, history of medication, alcoholism and Active smoking.

Sample collection

About 5 ml of venous blood was collected from all the subjects for the study for biochemical analysis.

Sample Analysis

Serum creatinine was estimated by alkaline picrate method [11], blood urea was estimated by Urease method [12], serum calcium level was estimated by OCPC method [13] and serum phosphorous was estimated by Ammonium Molybdate method [14]. Serum 25 OH vitamin D and serum will be analyzed by ELISA method [15]. Serum PTH was estimated by ELISA method [16].

Estimated GFR (eGFR)

Estimated GFR will be computed by employing Mayo Clinic Quadratic Equation (MCQE) based on serum creatinine and age in years [17].

The MCQE estimated GFR (ml/min/1.73m²)

=exp [1.911+5.249/SCr-2.114/SCr²-(0.00686 x age (years))(-0.205 if female)]

Carotid artery intima media thickness Test

Carotid artery ultrasound scans will be recorded for each participant with a 10-MHz linear-array transducer to measure intima media thickness (IMT) in the far wall of the right and left common carotid arteries within 2 cm proximal to the carotid bulb. The region with the thickest IMT, excluding areas with focal lesions, will be measured. The average IMT will be calculated from the right and left IMT measurements. All focal plaques within the carotid tree (common, internal, and external carotid arteries and bulb) will be identified as wall thickness. The area of each plaque will be calculated as the average lesion thickness (in mm) multiplied by the lesion length (in mm). In those participants with multiple plaques, plaque area will be the sum of the areas of all plaques observed in the carotid tree [18].

Statistical analysis

Data will be expressed in Mean and Standard deviation (mean ±SD). Unpaired student's t-test will be used for comparison of means between controls and cases. The statistical significance will be determined at 5% (p < 0.05) level. Comparison of means across the groups will be done by ANOVA. Vitamin D, Parathyroid hormone and CIMT will be correlated with eGFR by Spearman correlation.

RESULTS

Table1: Demographic data between Control and Cases

Parameter	Control(n=20)	CKD Stage 3(n=20)	CKD Stage 4(n=20)	CKD Stage 5(n=20)
Age(years) Mean±SD	50.95±8.30	48.85±9.64	50.45±7.49	52.30±6.86
Sex: Male/female	15/5	15/5	12/8	14/6

The above table shows age and sex matched individuals were considered for the study.

Table2: Blood urea, creatinine and eGFR between Control and Cases

Parameter	Control(n=20)	CKD Stage 3(n=20)	CKD Stage 4(n=20)	CKD Stage 5(n=20)	ANOVA
Blood Urea (mg/dL) Mean ±SD	19.75±4.20	52.25±11.19	81.15±24.56	116.45±16.80	F=131.129 p<0.0001
Serum Creatinine (mg/dL)Mean±SD	0.92±0.13	2.01±0.13	3.07±0.31	6.01±0.42	F=1251.18 p<0.0001
eGFR (mL/min)Mean±SD	126.68±14.45	39.54±4.27	20.01±3.83	9.85±1.14	F=932.420p<0.0001

The above table shows the mean blood urea and serum creatinine were significantly higher in CKD patients when compared with control. The mean serum eGFR was significant lower in CKD patients when compared with Control.

Table3: Serum Calcium and Phosphorus level between Control and Cases

Parameter	Control(n=20)	CKD Stage 3(n=20)	CKD Stage 4(n=20)	CKD Stage 5(n=20)	ANOVA
Serum Calcium(mg/dL) Mean±SD	10.17±0.65	8.78±0.42	8.59±0.22	7.98±1.90	F=16.087p<0.001
Serum Phosphorus(mg/dL) Mean±SD	3.66±0.27	4.38±0.35	4.97±0.56	5.65±0.35	F=90.979p<0.001

The above table shows the mean serum calcium was significantly lower in CKD patients when compared with control. The mean serum PTH was significant higher in CKD patients when compared with Control.

Table4: Serum Vitamin D and PTH level between Control and Cases

Parameter	Control (n=20)	CKD Stage 3(n=20)	CKD Stage 4(n=20)	CKD Stage 5(n=20)	ANOVA
Serum VitaminD(ng/mL) Mean±SD	42.50±4.45	30.90±4.33	24.95±2.98	21.45±3.45	F=115.067p<0.0001
Serum PTH(pg/mL) Mean±SD	39.75±3.04	82.10±10.56	103.90±12.45	212.60±36.32	F=272.147p<0.0001

The above table shows the mean serum Vitamin D was significantly lower in CKD patients when compared with control. The mean Serum PTH was significant higher in CKD patients when compared with Control.

Table5: CIMT level between Control and Cases

Parameter	Control(n=20)	CKD Stage 3(n=20)	CKD Stage 4(n=20)	CKD Stage 5(n=20)	ANOVA
CIMT Left side(mm) Mean±SD	0.50±0.06	0.72±0.05	0.82±0.05	0.85±0.04	F=196.797 p<0.0001
CIMT Right side(mm) Mean±SD	0.49±0.05	0.71±0.05	0.80±0.05	0.86±0.04	F=231.209 p<0.0001
Mean CIMT(mm) Mean±SD	0.50±0.06	0.72±0.05	0.81±0.05	0.86±0.04	F=198.889 p<0.0001

The above table shows the Carotid Intima Media Thickness (CIMT) both Left and Right side were significant higher in CKD patients when compared with Control. The mean CIMT was significantly higher in CKD patients compared with control. The increase is statistically significant (p<0.0001).

Table6: Correlation of Vitamin D, PTH and CIMT with eGFR

Parameter	Control(n=20)	CKD Stage 3(n=20)	CKD Stage 4(n=20)	CKD Stage 5(n=20)
Vitamin D	r=-0.30727 (p=0.0975)	r= 0.05396 (p=0.4107)	r=-0.01983 (p=0.4669)	r= 0.54034 (p=0.0045)
PTH	r=0.00303 (p=0.4949)	r= 0.1074 (p=0.3261)	r=0.37625 (p=0.0510)	r=-0.88412 (p<0.0001)
CIMT	r=0.19358 (p=0.2067)	r=-0.27108 (p=0.1239)	r=-0.56712 (p=0.0045)	r=-0.80244 (p<0.0001)

The above tables shows Vitamin D, PTH and CIMT were not correlated to eGFR in control, CKD stage 3 and. In CKD stage 4 Vitamin D and PTH were not correlated to eGFR whereas CIMT was negatively correlated with eGFR and it is statistically significant. In CKD stage 5 Vitamin D was positively correlated with eGFR and it is statistically significant. (p<0.001). PTH and CIMT were negatively correlated with eGFR and it is statistically significant. (p<0.001).

DISCUSSION

In the present study vitamin D, PTH and carotid artery intima media thickness in Chronic Kidney Disease have been assayed along with its Correlation with estimated Glomerular Filtration Rate. The diagnosis of Chronic Kidney Disease was made on the basis of history, physical examination, routine investigation, specific biochemical investigations and ultrasonographic findings.

In present study, 80 subjects were taken up for study to determine the vitamin D, PTH and carotid artery intima media thickness and divided in to control and CKD cases. Controls group consists of 20 subjects and CKD cases are further divided in CKD Stage 3, CKD Stage 4 and CKD Stage 5 each CKD stage contains 20 subjects each. Investigations were carried out in each case to assess their biochemical parameters and relevant information were gathered and tabulated.

In the present study it has been observed that mean age of control was 50.95, In CKD Stage3 it was 48.85, In CKD Stage 4 it was 50.45 and CKD Stage 5 it was 52.30. It has been observed that most of subjects are male, in control group 15 were male and 5 were female. In CKD Stage 3 group 15 were male and 5 were female, In CKD Stage 4 group 12 were male 8 were female and CKD Stage 5 group 14 were male and 6 were female.

In the present study the mean blood urea in CKD Stage 3, CKD Stage 4 and CKD Stage 5 were 52.25, 81.15 and 116.45 respectively and these are higher than that of control (19.75). This increase is statistically significant (p<0.0001). In the present study the mean Serum Creatinine in CKD Stage3, CKD Stage4 and CKD Stage5 were 2.01, 3.07 and 6.01 respectively and these are higher than that of control(0.92). This increase is statistically significant (p<0.0001). The increased blood urea and serum creatinine in CKD patients is due to decline in glomerular filtration.

In the present study the mean estimated GFR in CKD Stage 3, CKD Stage 4 and CKD Stage 5 were 39.54, 20.01 and 9.85 respectively and these are lower than that of control (126.68). This decrease is statistically significant (p<0.0001). Renal impairment exact status cannot provide by serum creatinine alone. Appreciable increase of serum creatinine required 50% fall in GFR. Estimated GFR based serum creatinine will provide more accurate results. Increased serum creatinine and decreased eGFR was identified in CKD in this present study it was similar to the findings of Chijioko et. al, [19], Increased mean serum creatinine shows late presentation of CKD cases in this study it was same findings of Ifeoma et al, It is because most of the CKD patients were under conservatively therapy than renal replacement therapy (RRT) [20].

In the present study the mean serum calcium in CKD Stage 3, CKD Stage 4 and CKD Stage 5 were 8.78, 8.59 and 7.98 respectively and these are lower than that of control (10.17). This decrease is statistically significant (p<0.0001). In the present study the mean Serum Phosphorus in CKD Stage3, CKD Stage4 and CKD Stage5 were 4.38, 4.97 and 5.65 respectively and these are higher than that of control (3.66). This increase is statistically significant (p<0.0001).

In the present study the mean serum Vitamin D in CKD Stage 3, CKD Stage 4 and CKD Stage 5 were 30.90, 24.95 and 21.45 respectively and these are lower than that of control (42.50). This decrease is statistically significant (p<0.0001). In the present study the mean Serum PTH in CKD Stage3, CKD Stage4 and CKD Stage5 were 82.10, 103.90 and 212.60 respectively and these are higher than that of control (39.75). This increase is statistically significant (p<0.0001). Declined kidney function leads to decreased vitamin D synthesis. Vitamin D inhibit cyclin-dependent kinase-2 activity and further causes suppression vascular smooth muscle cell proliferation [21]. In CKD decreased vitamin D associated with increased CIMT value. In this study mean serum calcium and Vitamin D were lowered in CKD patients than controls. Whereas serum phosphate and parathyroid hormone level were increased in CKD patients than in control.

In the present study the mean CIMT left side in CKD Stage 3, CKD Stage 4 and CKD Stage 5 were 0.72, 0.82 and 0.85 respectively and these are higher than that of control (0.50). This increase is statistically significant (p<0.0001). The mean CIMT right side in CKD Stage 3, CKD Stage 4 and CKD Stage 5 were 0.71, 0.80 and 0.86 respectively and these are higher than that of control (0.49). This increase is statistically significant (p<0.0001). The mean CIMT in CKD Stage3,

CKD Stage4 and CKD Stage5 were 0.72, 0.81 and 0.86 respectively and these are higher than that of control (0.50). This increase is statistically significant ($p < 0.0001$). Lu Xia Zhang et. al, study reported that in CKD stage 2 and 3 CIMT was significantly raised and concluded the progression CKD will causes arterial change. [22] Preston et. al, shown that Stage 3 and 4 have raised CIMT compared with Normotensive.[23] Atherosclerotic changes in carotid arteries might be indicative of atherosclerosis of coronary arteries. CIMT is a non-invasive marker for generalized atherosclerosis and good indicator for coronary heart disease.

In the present study correlation of Vitamin D, PTH and CIMT with eGFR was conducted. In control and CKD stage3 Vitamin D, PTH and CIMT were not correlated to eGFR and it is not statistically significant. In CKD stage 4 Vitamin D ($r = -0.01983$) and PTH ($r = 0.37625$) were not correlated to eGFR whereas CIMT ($r = -0.56712$) was negatively correlated with eGFR and it is statistically significant ($p < 0.001$). In CKD stage 5 Vitamin D ($r = 0.54034$) was positively correlated with eGFR and it is statistically significant ($p < 0.001$). PTH ($r = -0.88412$) and CIMT ($r = -0.80244$) were negatively correlated with eGFR and it is statistically significant ($p < 0.001$).

The present study findings correlation of biochemical parameters in different stages of CKD is found similar to Rahman et. al., It has noted that decreased calcium, decreased vitamin D, increased phosphate and hyperparathyroidism are most important features of CKD [24]. This is similar to study of Malawadi et. al., it also shown increased serum phosphate and parathyroid and also shown decreased levels of serum calcium and eGFR compared to the control the study does not shown vitamin D Status [25].

In this present study regarding PTH and eGFR was comparable to the Rahman et. al., study they also correlated the parathyroid hormone with biochemical parameters in chronic kidney disease Ian H. de Boer et al, study shown increased PTH value as the advanced stage of CKD [26]. Stalopoulos et al, study confirmed that increased PTH is a most common feature of CKD [27]. The high levels of mean PTH due to reduced serum calcium and continuous increase of serum phosphate from early to advanced renal failure. The handling of calcium by renal system differs in different stage of CKD. This type of trend is mostly identified from CKD stage 3 onwards.

This study helpful to label an early alarming marker to prevent the worst progression of CKD by estimating Vitamin D, PTH and CIMT. The progression and complications of CKD, especially the cardiovascular complications can be prevented or at least postponed to some extent. Supplementation of vitamin D along with calcium would be more beneficial. A chelating phosphate molecule would be a challenge in the coming years to add to the benefits of the treatment for CKD. The quality of life can be improved for the CKD patients to a near normal condition.

Conflict of interest: No conflict of interest

REFERENCES

1. Gooneratne IK, Ranaweera AK, Liyanarachchi NP, Gunawardane N, Lanerolle RD. Epidemiology of chronic kidney disease in a Sri Lankan population. *International journal of diabetes in developing countries*. 2008 Apr; 28(2):60.
2. Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, Tsai SP, Chiang PH, Hsu CC, Sung PK, Hsu YH, Wen SF. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. *The Lancet*. 2008 Jun 28; 371(9631):2173-82.
3. Singh AK, Farag YM, Mittal BV, Subramanian KK, Reddy SR, Acharya VN, Almeida AF, Channakeshavamurthy A, Ballal HS, Gaccione P, Issacs R. Epidemiology and risk factors of chronic kidney disease in India—results from the SEEK (Screening and Early Evaluation of Kidney Disease) study. *BMC nephrology*. 2013 Dec; 14(1):114.
4. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. *American Journal of Kidney Diseases*. 1998 Nov 1; 32(5):853-906.
5. Artaza JN, Mehrotra R, Norris KC. Vitamin D and the cardiovascular system. *Clinical Journal of the American Society of Nephrology*. 2009 Sep 1; 4(9): 1515-22.
6. Melamed ML, Astor B, Michos ED, Hostetter TH, Powe NR, Muntner P. 25-hydroxyvitamin D levels, race, and the progression of kidney disease. *Journal of the American Society of Nephrology*. 2009 Oct 29; ASN-2009030283.
7. Michos ED, Reis JP, Post WS, Lutsey PL, Gottesman RF, Mosley TH, Sharrett AR, Melamed ML. 25-Hydroxy vitamin D deficiency is associated with fatal stroke among whites but not blacks: The NHANES-III linked mortality files. *Nutrition*. 2012 Apr; 28(4):367-71.
8. C Brewer L, D Michos E, P Reis J. Vitamin D in atherosclerosis, vascular disease, and endothelial function. *Current drug targets*. 2011 Jan 1; 12(1):54-60.
9. DeBoer IH, Kestenbaum B, Shoben AB, Michos ED, Samak MJ, Siscovick DS. 25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. *Journal of the American Society of Nephrology*. 2009 Aug 1; 20(8):1805-12.
10. London GM, Guérin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, Métivier F. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. *Journal of the American Society of Nephrology*. 2007 Feb 1; 18(2):613-20.
11. Bowers LD. Kinetics of serum creatinine assays I. The role of various factors in determining specificity. *Clinical Chemistry*. 1980 Apr 1; 26(5):551-4.
12. Tiffany TO, Jansen JM, Burtis CA, Overton JB, Scott CD. Enzymatic kinetic rate and end-point analyses of substrate, by use of a Ge MSAEC fast analyzer. *Clinical Chemistry*. 1972 Aug 1; 18(8):829-40.
13. Moorehead WR, Biggs HG. 2-Amino-2-methyl-1-propanol as the alkalinizing agent in an improved continuous-flow cresolphthalein complex one procedure for calcium in serum. *Clinical Chemistry*. 1974 Nov 1; 20(11):1458-60.
14. Daly JA and Ertlingshausen G. Estimation of phosphorus by ammonium molybdate method. *Clinical Chemistry* 1972; 18:263.
15. Holick MF. Vitamin D status: Measurement, interpretation and clinical application. *Ann Epidemiol*. 2009; 19(2):73-78.
16. Lepage R, Roy L, Brossard J, Rousseau L, Dorais C, Lazure C, Damour P. Circulating PTH fragment interfere significantly with intact PTH commercial assay measurement in uremic samples. *Clinical Chemistry*. 1998; 44,4,805-809.
17. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. *Annals of Internal Medicine*. 2004 Dec 21; 141(12):929-37.
18. Salonen JT, Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. *Arteriosclerosis, thrombosis, and vascular biology*. 1991 Sep 1; 11(5):1245-9.

19. Chijioke,A.,Aderibigbe,A.,Olarenwaju,T.O.,Makusidi,A.M.,Oguntoyinbo,A.E. Prevalence and pattern of cystic kidney diseases in Ilorin, Nigeria. *Saudi Journal of Kidney Diseases and Transplantation*, 2010 21(6),1172.
20. Ifeoma I U, Chinwuba K I, The enormity of chronic kidney disease in Nigeria: The situation in a teaching hospital in south east Nigeria. *J Trop Med*. 2010; 2010:1-6
21. Lim S, Shin H, Kim MJ; Ahn HY, Kang SM, Yoon JW, et al. Vitamin D effects endothelium in terms of calcium deposition and increased coronary artery calcification score. *J Clin Endocrinol Metab*.2012;97(1):169-78.
22. Zhang L, Zuo L, Wang F, Wang M, Wang S, Lv J, et al. Cardiovascular disease in early stages of chronic kidney disease in a Chinese population. *J Am Soc Nephrol*.2006;17(9):2617-21.
23. Preston E, Ellis MR, Kulinskaya E, Davies AH, Brown EA. Association between carotid artery intima-media thickness and cardiovascular risk factors in CKD. *Am J Kid Dis*. 2005;46(5):856-62.
24. Rahman MH, Hosain MM, Sultana S, Jamal CY, Karim MA. Correlation of Serum parathormone level with biochemical parameters in chronic renal failure. *Indian Pediatrics* 2005;42:250-54.
25. Malawadi, BN, Suma MN, Prashant V, Akila P, Anjalidevi BS, Manjunath S. "Secondary hyperparathyroidism in all the stages of chronic kidney disease in south Indian population." *IJPPS*2014;4:6
26. Ian H, Inina Gorodetskaya, Belinda Young, Chi-yuan, Glenn MC. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR dependent ,race dependent and associated with cardiovascular disease. *J Am Soc Nephrol* 2002;13:2762-69.
27. Slatopolsky E, Firch J, Denda M, Ritter C, Zhong M, Dusso A, et al. Phosphate restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion invitro. *J Clin Invest* 1996; 97(11):2534.